Devices

Shenzhen Weifa Technology Co., Ltd

FDA issued a warning letter to Shenzhen Weifa Technology Co., Ltd (Shenzhen Shi, Guangdong Sheng, China) on Mar 11, 2021, citing 21 CFR 807.39. Subject: Investigational Device Exemptions (IDE), Premarket Approval Application (PMA) Adulterated Device.

From the letter: “The FFP1 3-ply Non-Woven EarLoop Mask and the N95/FFP2 Respirator*1* are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA.”

Shenzhen Shi, Guangdong Sheng, ChinaIssued Mar 11, 2021Posted Mar 16, 2021Close-out Sep 27, 2021

FDA published a close-out letter on Sep 27, 2021. The findings below are from the original warning letter.

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
7 findings · 2 issue types
Response due
Not stated in the letter
FDA asks for
4 actions
Named as possible actions
Refusal of admission
Issued by
Center for Devices and Radiological Health
Published status
Close-out Sep 27, 2021

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Registration, listing & premarketDevices offered for sale without required premarket approval or investigational device exemption, rendering them adulterated.
The FFP1 3-ply Non-Woven EarLoop Mask and the N95/FFP2 Respirator*1* are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g).
02Registration, listing & premarketDevices misbranded because firm failed to notify FDA of intent to introduce devices into commercial distribution as required by section 510(k).
These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).
03Labeling, claims & marketing · 21 CFR 807.39Devices misbranded because labeling falsely states they are 'FDA certificated' and includes misleading references to FDA registration.
In addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95/FFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95/FFP2 Respirator are misleading and constitute misbranding. *See* 21 CFR 807.39.
04Labeling, claims & marketingWebsite falsely states devices are 'FDA certificated' and 'official certificated…FDA.'
Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.”
05Labeling, claims & marketingUnauthorized display of FDA's logo alongside product information is misleading.
Unauthorized display of FDA’s logo*2* alongside the devices’ product information.
06Labeling, claims & marketingDisplaying a 'Certification of FDA Registration' from a third party with unauthorized FDA logo misleads consumers into believing FDA approval.
Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95/FFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” and incorporates, unauthorized use of the FDA logo*2*.
07Labeling, claims & marketing · 21 CFR 807.39Combined display of FDA logo and Certification implies FDA approval despite disclaimer, misleading consumers.
In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95/FFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95/FFP2 Respirator and/or establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification.

What FDA requested

  • Provide specific steps taken to address the noted violations
  • Provide an explanation of how the firm plans to prevent these violations or similar violations from occurring again
  • Provide documentation of any corrections and/or corrective actions taken
  • If planned corrections will occur over time, provide a timetable for implementation

FDA Warning Letter

29 paragraphs · 1 section

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

Sent toDATE: March 11, 2021
Re: FFP1 3-ply Non-Woven EarLoop Mask and N95/FFP2 Respirator
AddressedDear Huaquan Yu

1Letter text

25 paragraphs

This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address www.starkit.com, on February 2, 2021, where you offered the “FFP1 3-ply Non-Woven EarLoop Mask” and “N95/FFP2 Respirator” for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).

The FFP1 3-ply Non-Woven EarLoop Mask and the N95/FFP2 Respirator1 are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).

In addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95/FFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95/FFP2 Respirator are misleading and constitute misbranding. See 21 CFR 807.39.

Your website contains a number of false and/or misleading representations, including but not limited to:

• Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.” • Unauthorized display of FDA’s logo2 alongside the devices’ product information. • Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95/FFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” and incorporates, unauthorized use of the FDA logo2.

To date, FDA has not “certificated” the FFP1 3-ply Non-Woven EarLoop Mask and the N95/FFP2 Respirators, and statements to the contrary are false. In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95/FFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95/FFP2 Respirator and/or establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the N95/FFP2 Respirator has been reviewed and approved by FDA.

We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue any type of device registration certificates to medical device establishments, including sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database does not denote anything other than that the establishment has provided certain information to FDA.

This letter is not meant to be an all-inclusive list of violations that exist in connection with the product or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.

This letter notifies you of our concerns and provides you with an opportunity to address them.

Please notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any corrections and/or corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.

Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:

Food and Drug Administration Center for Devices and Radiological Health Office of Regulatory Programs Division of Regulatory Programs 2: Establishment Support Regulatory Inspections and Audits Team White Oak Building 66 10903 New Hampshire Ave. Silver Spring, MD 20993

Refer to the Document number CMS Case# 609828 or CTS Number CPT2000946 when replying. We remind you that only written communication is considered as official.

If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.

/S/

Donna Engleman, MS, BSN Director Division of Market Intelligence Office of Regulatory Programs Office of Product Evaluation and Quality Center for Devices and Radiological Health

Cc:

Angla Li US Agent 4402 Gertrude Dr Fremont, CA 94536 xv393fbhh@sina.cn

Alan Lin Shenzhen CCT Testing Technology Co. Ltd. 6F, Fazhan Building, No.04, Shangwu Road, Shiyan Town, Bao'an District, Shenzhen, Guangdong, 518108 China fda@fda-test.com

Fei Leng Gaomishi Zhonghexiang Labor Products Industry & Trade Company 2th.Zhilan Village, Chaoyang District, Gaomi City, Shandong Province, Weifang Shandong, CN 261500

Medical Facility Company US Agent 555 Lexington Avenue Fort George, NY 10040 SpecifyA@163.com

_____________________

1 Your website indicates the N95/FFP2 Respirator is manufactured by “Gaomishi Zhonghexiang labor products industry &Trade Co., Ltd.”

2 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https://www.fda.gov/about-fda/website-policies/fda-logo-policy).

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Devices and Radiological Health
Issuing office
Center for Devices and Radiological Health
Location
Shenzhen Shi, Guangdong Sheng, China
Letter posted date
Mar 16, 2021
Letter issue date
Mar 11, 2021
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
Not verified in this snapshot. Consult the original letter.
Record length
1,258 words · 0 recorded redactions
Published status
Close-out published Sep 27, 2021
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More medical-device letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.